No Data
'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News
This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.Hello, friends! I'm in Sa
PDS Biotechnology | 10-Q: Quarterly report
Buy Rating Affirmed for PDS Biotechnology on Strong Financials and Promising Clinical Pipeline
PDS Biotechnology (PDSB.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.30 dollars, previous value of -0.32 dollars, expected value of -0.37 dollars.
PDS Biotechnology (PDSB.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.30 dollars, previous value of -0.32 dollars, expected value of -0.37 dollars.
PDS Biotechnology Q1 2024 GAAP EPS $(0.30) Beats $(0.37) Estimate, Cash $66.6M
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 6.25 percent increase over losses of $(0
PDS Biotechnology 1Q Research and Development Expenses $6.7M >PDSB
PDS Biotechnology 1Q Research and Development Expenses $6.7M >PDSB